Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise

Prokidney

10/08/2026 21:22

Overview
U.S. cell therapy developer's Q2 operating expenses rose, driven by clinical study and manufacturing costs
Net loss widened in Q2 compared to prior yr
Company completed enrollment for PROACT 1 accelerated approval efficacy analysis, with topline results expected Q2 2027

Outlook
Company expects topline eGFR slope results from PROACT 1 in Q2 2027
ProKidney on track to complete full PROACT 1 enrollment in second half of 2026
Company says current cash supports operations into mid-2027

Result Drivers
CLINICAL STUDY COSTS - Higher R&D expenses in Q2 were driven by increased clinical study and related manufacturing costs for the ongoing PROACT 1 trial
LOWER ADMINISTRATIVE COSTS - General and administrative expenses fell due to lower compensation costs and reduced professional fees
ENROLLMENT MILESTONE - Completion of enrollment for PROACT 1 accelerated approval efficacy analysis marked a key operational milestone

Company press release: ID:nGNXchhgj3

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Operating Expenses
 
$48.52 mln
 
Q2 Operating Income
 
-$48.37 mln
 
Q2 Pretax Loss
 
$46.44 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Prokidney Corp is $7.00, about 326.8% above its August 7 closing price of $1.64

Reuters Recommended Reads
Aug 10 - Cogent Biosciences Q2 net loss widens on higher expenses
Aug 10 - Oruka Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Jade Biosciences Q2 net loss widens as costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)